Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.
about
Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug actionIntegrating Multiscale Modeling with Drug Effects for Cancer TreatmentImplementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchPharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireviewPharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjectsDeriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis dataUsing physiologically based models for clinical translation: predictive modelling, data interpretation or something in-between?An Algorithm and R Program for Fitting and Simulation of Pharmacokinetic and Pharmacodynamic Data.Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model.Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.In vivo activity of cefquinome against Escherichia coli in the thighs of neutropenic miceTheoretical basis for the identification of allelic variants that encode drug efficacy and toxicity.Pharmacokinetic and pharmacodynamic analysis comparing diverse effects of detomidine, medetomidine, and dexmedetomidine in the horse: a population analysis.Concepts and challenges in quantitative pharmacology and model-based drug development.Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MICA Systems Biology Approach in Therapeutic Response Study for Different Dosing Regimens-a Modeling Study of Drug Effects on Tumor Growth using Hybrid SystemsQuantitative Systems Pharmacology Approaches Applied to Microphysiological Systems (MPS): Data Interpretation and Multi-MPS Integration.Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents.The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.Dose-escalation study of octanoic acid in patients with essential tremor.Dynamical modeling of drug effect using hybrid systems.Kinetic analysis of drug-target interactions with PET for characterization of pharmacological hysteresis.On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development.Microfluidic technique to measure intratumoral transport and calculate drug efficacy shows that binding is essential for doxorubicin and release hampers Doxil.The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.In vitro pharmacodynamic models to determine the effect of antibacterial drugs.A passage through systems biology to systems medicine: adoption of middle-out rational approaches towards the understanding of therapeutic outcomes in cancer.The Øie-Tozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior.Role of modelling and simulation: a European regulatory perspective.Physiologically based pharmacokinetic (PBPK) modeling in children.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Automation of anaesthesia: a review on multivariable control.Mathematical modeling analysis of intratumoral disposition of anticancer agents and drug delivery systems.Organ-on-a-chip: development and clinical prospects toward toxicity assessment with an emphasis on bone marrow.Tools for predicting the PK/PD of therapeutic proteins.Use of pharmacy records to measure treatment adherence: a critical review of the literature.Beyond conventional antibiotics - New directions for combination products to combat biofilm.
P2860
Q24595639-A52EC98A-D611-4CE2-B7B5-B5A9538D350DQ26770510-4F308155-ED08-41E6-B883-ED23CF0D189DQ27024682-4E3074D9-E77F-4936-8994-6D9369B2B120Q27025071-E7F4A61E-5830-435C-A4BE-FF7F31C2CA3CQ28169037-29E77E95-63C1-43D8-8C12-16D010970AD5Q30700231-BF6C690B-C728-442E-A697-638C8A4DE1ACQ31086222-0282BAAA-158F-40B3-BD23-1909306EFA93Q31119393-0C67204A-A96F-4E9D-9EBF-6309637C9BADQ33716001-766B277B-B204-4E08-AC5C-6236122B5485Q33906751-B06DAE11-5491-4B30-BF65-E47200D332F6Q34293586-4B4B984F-34FC-49BB-B2D8-664C329F02FBQ34299028-23FEA740-1A12-4624-8DAC-C4391594F1A2Q34575544-15063E72-894A-4DB2-AB67-D123666340A4Q34860261-7ABC64CF-0B1B-4825-AC80-F9BEC7BFA134Q34878168-4EFCC660-53EE-47FA-B8B6-732DB076A393Q35125148-F4D8FC37-DA8E-4014-89F2-C5A9970D5FF3Q35637864-267F3D7F-A315-44A4-8E10-755198039CECQ35817902-6565447F-994C-49CC-B8B5-58836F3C37C6Q35831603-B6546A14-D07D-45E6-9251-482050CDC893Q36162355-9F90BA2D-5E5E-420B-990F-436BBE45A6BDQ36599937-C5458462-B83B-426B-8685-42091D98142DQ36667227-5257396E-9C55-40E2-8059-0A6EAFA416E3Q36737977-178A4053-B45E-46AD-ABD1-D275DB2A8610Q36803684-4D25AB5C-33A8-49AA-B4B4-91D6853AA27EQ36839978-E34D0D1B-6819-43E8-99E3-B09E437B68C7Q36985094-2D5BBD22-7297-42F1-A5EA-4CDD517C7EDAQ37141366-82986F3C-3AAE-4ACA-94D0-CF72BCE04EC0Q37521422-B66342C8-7D10-4690-BB05-059DAF5D7E79Q37660762-EA596E4D-7FCA-4938-B292-55587DD8B819Q37812550-A4A0C7C6-91E2-4764-926C-BB17AFA4C898Q37932558-7B7CFDB9-A81D-4CD2-B5B2-BA11CC8984CEQ37976876-70DD270D-A0AD-4823-8916-46AEDAA31758Q38016332-A46E07F7-D6B8-4D65-837E-78B4B6AC7AF4Q38110433-16C6DC91-D980-4678-8692-F5EE15CF1489Q38222877-95ADFF99-6A6D-478B-9BD7-CE9144251B6CQ38392523-FE3CE6A9-7CAA-4135-AD5C-37061382C111Q38395139-DE830550-3C7C-42D1-9BDB-CDF6123E3E05Q38455786-C2BBB59A-8522-4424-9831-7AFB4F9CD279Q38819475-197529B7-6324-4446-B268-291FA7DD5C57Q38920223-409C8F2F-24CC-46CF-B9E4-E6066C8E1651
P2860
Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Modeling of pharmacokinetic/ph ...... ps: concepts and perspectives.
@ast
Modeling of pharmacokinetic/ph ...... ps: concepts and perspectives.
@en
type
label
Modeling of pharmacokinetic/ph ...... ps: concepts and perspectives.
@ast
Modeling of pharmacokinetic/ph ...... ps: concepts and perspectives.
@en
prefLabel
Modeling of pharmacokinetic/ph ...... ps: concepts and perspectives.
@ast
Modeling of pharmacokinetic/ph ...... ps: concepts and perspectives.
@en
P356
P1476
Modeling of pharmacokinetic/ph ...... ps: concepts and perspectives.
@en
P2093
Derendorf H
P304
P356
10.1023/A:1011907920641
P577
1999-02-01T00:00:00Z